Moderna (MRNA)
(Delayed Data from NSDQ)
$84.93 USD
+0.61 (0.72%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $85.09 +0.16 (0.19%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$84.93 USD
+0.61 (0.72%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $85.09 +0.16 (0.19%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Zacks News
Markets Set New Record Closes; FedEx Beats on Q2
by Mark Vickery
It's the S&P 500's 31st all-time closing high this year, and Nasdaq is on pace for its strongest full-year performance since 2009.
TIPS ETFs to Buy for 2021 on Inflation Trade
by Sweta Killa
The COVID-19 vaccines and their availability have raised the prospect of inflation as we move ahead into the next year.
Moderna Vaccine: The Power of mRNA Technology
by Kevin Cook
Warp speed was just the ticket to launch top COVID-19 vaccines -- and a revolution in medicine
Biotech Stock Roundup: ALXN Up on Acquisition News, PFE-BNTX Get EUA for Vaccine & More
by Zacks Equity Research
Coronavirus vaccine updates from Moderna (MRNA) and Pfizer (PFE)/BioNTech (BNTX) and Alexion's (ALXN) acquisition grab headlines this week.
The Zacks Analyst Blog Highlights: Pfizer, Trane Technologies, United Parcel Service, FedEx and Moderna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Trane Technologies, United Parcel Service, FedEx and Moderna
Moderna (MRNA) Vaccine May Get Emergency Approval This Week
by Zacks Equity Research
An advisory committee meeting is scheduled on Dec 17 to discuss emergency use authorization for Moderna's (MRNA) COVID-19 vaccine candidate, mRNA-1273.
Stock Market News for Dec 16, 2020
by Zacks Equity Research
Wall Street closed sharply higher on Tuesday buoyed by investors' renewed hopes for a fresh round of coronavirus-aid package by this week end.
Earn 7% Plus Yield With These ETFs
by Sanghamitra Saha
These ETFs offer at least 7% in annual yield.
Industrial Production Beats Expectations in November
by Zacks Equity Research
Industrial Production Beats Expectations in November.
Sector ETFs to Gain the Most on COVID-19 Vaccine Rollout
by Sweta Killa
The United States has geared up for the largest-ever immunization with the rollout of the COVID-19 vaccine.
Markets Swing Back Up on Vaccine Positivity
by Mark Vickery
Import Prices, Empire State and Industrial Production numbers join new positive data from the FDA on Moderna's (MRNA) vaccine candidate.
CureVac (CVAC) Begins Pivotal Study on COVID-19 Vaccine
by Zacks Equity Research
CureVac (CVAC) doses the first patient in a pivotal study on its COVID-19 vaccine candidate, CVnCoV. Shares rise following this development.
5 Stocks to Win Big as Coronavirus Vaccine Rollout Begins
by Tirthankar Chakraborty
Emergency approval of COVID-19 vaccines is a boon for stocks such as Trane Technologies (TT), United Parcel Service (UPS), FedEx (FDX), Pfizer (PFE) and Moderna (MRNA). Here's why -
Why IPO ETFs are Soaring in 2020
by Neena Mishra
These ETFs provide diversified exposure to hottest IPOs
Wall Street Surges on COVID-19 Vaccine Approval
by Zacks Equity Research
Wall Street Surges on COVID-19 Vaccine Approval.
6 Consumer Discretionary ETFs Riding on Holiday Fervor
by Sweta Killa
U.S. consumers grew more confident in the economy in early December on the prospects of a vaccine, which has bolstered the holiday mood.
Historic Day for Pfizer (PFE), Covid-19 Vaccine
by Mark Vickery
With more than 180K daily reported cases as of yesterday, with more than 109K hospitalizations and nearly 1500 deaths on Sunday alone, this vaccine availability is not just historic, it's momentous.
Stocks Decline modestly, but Vaccine Optimism Promises a New Rally
by David Borun
A massive rollout of vaccine distribution is the best hope yet for a "return to normal."
ETFs to Win & Lose From the Surge in Oil Price
by Sweta Killa
Oil price has been on a surge in recent months buoyed by solid development on the COVID-19 vaccine front.
Biotech ETF (SBIO) Hits a New 52-Week High
by Sweta Killa
This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?
COVID-19 Vaccine Race Heats Up as Pfizer Gets Emergency Nod
by Kinjel Shah
FDA grants emergency use approval to Pfizer (PFE)/BioNTech's (BNTX) COVID-19 vaccine candidate.
5 Energy ETFs Making the Most of the Oil Rally
by Sweta Killa
After registering the best month ever, the energy sector continued its bullish trend on vaccine optimism,
Pfizer/BioNTech COVID-19 Vaccine Gets FDA Panel's Backing
by Zacks Equity Research
An FDA panel recommends granting approval for emergency use of Pfizer's (PFE)/BioNTech's (BNTX) COVID-19 vaccine
Moderna (MRNA) Starts COVID-19 Vaccine Study in Adolescents
by Zacks Equity Research
Moderna (MRNA) initiates development of its coronavirus vaccine candidate, mRNA-1273, in adolescent patients in a phase II/III study.
Implied Volatility Surging for Moderna (MRNA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.